Publications

Detailed Information

Deepening of eyelid superior sulcus during topical travoprost treatment

Cited 46 time in Web of Science Cited 58 time in Scopus
Authors

Yang, Hee Kyung; Park, Ki Ho; Kim, Tae-Woo; Kim, Dong Myung

Issue Date
2009-03
Publisher
SPRINGER TOKYO
Citation
JAPANESE JOURNAL OF OPHTHALMOLOGY; Vol.53 2; 176-179
Keywords
complicationseyelid sulcus deepeningtravoprost
Abstract
Topical travoprost, a prostaglandin F(2 alpha) (PGF(2 alpha)) analog, has several well-known side effects, including a darkening of the eyelid and eyelash hypertrichosis, but there are no reports of a deepening of the eyelid superior sulcus associated with its use. We examined one patient with unilateral normal-tension glaucoma and another with unilateral primary open-angle glaucoma, both of whom were treated with travoprost monotherapy unilaterally for 2 years. Both patients gradually developed a deepening of the eyelid superior sulcus with hyperpigmentation in the eyelid skin of the treated eye. The disparity between the treated eye and the fellow eye was quite visible. However, the disparity returned to normal after discontinuation of travoprost for 15 months. A deepening of the eyelid superior sulcus is more significant in Asians, who seldom have an eyelid crease or deep sulcus. One proposed mechanism is a mechanical insult to the eyelid causing levator dehiscence. A second possible mechanism is fatty degeneration and reduced collagen fibers in the levator complex caused by the PGF(2 alpha) analog. However, the exact mechanism remains to be determined. A deepening of the eyelid superior sulcus should be considered a possible complication of topical travoprost that can be reversed by discontinuation of the medication.
ISSN
0021-5155
Language
English
URI
https://hdl.handle.net/10371/78022
DOI
https://doi.org/10.1007/s10384-008-0623-x
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share